Cancelled by the investigator. Study on the efficacy and clinical prognosis of using different blood adsorption columns for the treatment of septic shock patients

Study on the efficacy and clinical prognosis of using different blood adsorption columns for the treatment of septic shock patients

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400089000

Enrollment

Unknown

Registered

2024-08-30

Start date

2024-09-01

Completion date

Unknown

Last updated

2024-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sepsis shock

Interventions

HA380 Group:On the basis of comprehensive internal medicine treatment, receive blood adsorption (HA380 blood adsorption column) treatment once a day for 3 consecutive days

CA280 Group:On the basis of comprehensive internal medicine treatment, receive blood adsorption (CA280 blood adsorption column) treatment once a day for 3 consecutive days.

Control group:Comprehensive internal medicine treatment

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.18-80 years old; 2. Meets the diagnostic criteria of Sepsis; 3. After sufficient fluid resuscitation, vasoactive drugs are required to make MAP = 65mmHg and blood lactate>2mmol/L; 4.IL-6=250pg/ml 5. Sign the informed consent form

Exclusion criteria

Exclusion criteria: 1. Patients with combined tumors; 2. Pregnant or lactating women; 3. Individuals with HIV infection or other immunodeficiency diseases; Subjects taking immunosuppressants, excluding corticosteroids. 4. Patients with combined active bleeding, disseminated intravascular coagulation, thrombosis, or thrombotic diseases; 5. Patients with a history of combined organ transplantation; Patients with unstable infarction caused by combined cardiovascular accidents; New York Heart Association (NYHA) Grade IV decompensated heart failure subjects; Subjects with chronic kidney disease (CKD) stage 5 or above; Subjects with end-stage liver failure. 6. Received blood adsorption therapy within one week before enrollment; 7. Individuals who are allergic to any component of the upcoming blood adsorption device; 8. Patients who cannot comply with research arrangements and refuse to sign informed consent forms; 9. Other situations deemed unsuitable for inclusion by researchers;

Design outcomes

Primary

Measure	Time frame
Mortality rate during hospitalization and 28 day mortality rate;ICU length of stay;	—

Secondary

Measure	Time frame
Inflammatory factors (CRP PCTIL-6IL-10TNF-a);Liver function;Renal function;Coagulation function;	—

Countries

China

Contacts

Public Contactkai kang

Harbin Medical University Affiliated First Hospital

Janekk79@126.com+86 139 0461 8016

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026